Biogen (BIIB), Eisai Expand Pact to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab
Tweet Send to a Friend
Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced today that the companies have expanded their existing agreement to jointly ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
